Study identifier:D9831C00002
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, placebo-controlled, randomised, parallel group phase IIa study to evaluate the histological changes, cellularity, clinical efficacy and safety of AZD1981 in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Phase 2
No
AZD1981, Placebo
All
52
Interventional
40 Years +
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Oct 2013 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: AZD1981 | Drug: AZD1981 Oral tablet, twice daily, 4 weeks treatment |
Placebo Comparator: Placebo | Drug: Placebo Placebo |